Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Long-Term Debt Repayments (2016 - 2020)

Viridian Therapeutics, Inc.\DE (VRDN) has 6 years of Long-Term Debt Repayments data on record, last reported at $9.0 million in Q4 2020.

  • For Q4 2020, Long-Term Debt Repayments rose 796.0% year-over-year to $9.0 million; the TTM value through Sep 2021 reached $9.0 million, up 284.05%, while the annual FY2020 figure was $10.3 million, 341.19% up from the prior year.
  • Long-Term Debt Repayments reached $9.0 million in Q4 2020 per VRDN's latest filing, up from $333000.0 in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $9.0 million in Q4 2020 and bottomed at $333000.0 in Q4 2016.
  • Average Long-Term Debt Repayments over 4 years is $1.6 million, with a median of $500000.0 recorded in 2017.
  • Peak YoY movement for Long-Term Debt Repayments: skyrocketed 1565.0% in 2016, then changed 0.0% in 2020.
  • A 4-year view of Long-Term Debt Repayments shows it stood at $333000.0 in 2016, then skyrocketed by 851.05% to $3.2 million in 2017, then crashed by 68.42% to $1.0 million in 2019, then soared by 796.0% to $9.0 million in 2020.
  • Per Business Quant database, its latest 3 readings for Long-Term Debt Repayments were $9.0 million in Q4 2020, $333000.0 in Q2 2020, and $1.0 million in Q1 2020.